Trace element supplementation in hemodialysis patients: a randomized controlled trial
Authors:
- For The Alberta Kidney Disease NetworkFNFor The Alberta Kidney Disease Network
- Marcello TonelliMTMarcello Tonelli
- Natasha WiebeNWNatasha Wiebe
- Stephanie ThompsonSTStephanie Thompson
- David KinniburghDKDavid Kinniburgh
- Scott W KlarenbachSKScott W Klarenbach
- Michael WalshMWMichael Walsh
- Aminu K BelloABAminu K Bello
- Labib FaruqueLFLabib Faruque
- Catherine FieldCFCatherine Field
- Braden J MannsBMBraden J Manns
- Brenda R HemmelgarnBHBrenda R Hemmelgarn
Open Access
- 11 April 2015
- journal article
- research article
- Published by Springer Nature in BMC Nephrology
- Vol. 16 (1) , 52
Abstract
People with kidney failure are often deficient in zinc and selenium, but little is known about the optimal way to correct such deficiency. We did a double-blind randomized trial evaluating the effects of zinc (Zn), selenium (Se) and vitamin E added to the standard oral renal vitamin supplement (B and C vitamins) among hemodialysis patients in Alberta, Canada. We evaluated the effect of two daily doses of the new supplement (medium dose: 50 mg Zn, 75 mcg Se, 250 IU vitamin E; low dose: 25 mg Zn, 50 mcg Se, 250 IU vitamin E) compared to the standard supplement on blood concentrations of Se and Zn at 90 days (primary outcome) and 180 days (secondary outcome) as well as safety outcomes. We enrolled 150 participants. The proportion of participants with low zinc status (blood level 0.99) or 180 days (18.6% vs 28.2%, P = 0.24). The proportion with low selenium status (blood level <121 ug/L) was similar for controls and the combined intervention groups at 90 days (32.6 vs 19.6%, P = 0.09) and 180 days (34.9% vs 23.5%, P = 0.17). There were no significant differences in the risk of adverse events between the groups. Supplementation with low or medium doses of zinc and selenium did not correct low zinc or selenium status in hemodialysis patients. Future studies should consider higher doses of zinc (≥75 mg/d) and selenium (≥100 mcg/d) with the standard supplement. Registered with ClinicalTrials.gov ( NCT01473914 )Keywords
This publication has 17 references indexed in Scilit:
- Paraoxonase Enzyme Activity Is Enhanced by Zinc Supplementation in Hemodialysis PatientsRenal Failure, 2012
- Trace Element Status in Hemodialysis PatientsSeminars in Dialysis, 2010
- Impact of oral zinc therapy on the level of sex hormones in male patients on hemodialysisRenal Failure, 2010
- Selenium bioavailability: current knowledge and future research requirementsThe American Journal of Clinical Nutrition, 2010
- Effects of Zinc Supplementation on Serum Zinc and C-Reactive Protein Concentrations in Hemodialysis PatientsJournal of Renal Nutrition, 2009
- Methods of assessment of zinc status in humans: a systematic reviewThe American Journal of Clinical Nutrition, 2009
- Methods of assessment of selenium status in humans: a systematic reviewThe American Journal of Clinical Nutrition, 2009
- Trace elements in hemodialysis patients: a systematic review and meta-analysisBMC Medicine, 2009
- Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: A simple assessment of symptom burdenKidney International, 2006
- Zinc-Induced Copper DeficiencyAmerican Journal of Clinical Pathology, 2005